{
  "id": "1ac4c1cb69b2e7b4",
  "title": "Komzifti Approved for Adults With R / R NPM1 - Mutated AML",
  "description": "20251222T183000Z",
  "content": "",
  "source": "cancertherapyadvisor.com",
  "source_url": "https://www.cancertherapyadvisor.com/news/komzifti-approved-for-adults-with-r-r-npm1-mutated-aml/",
  "published_at": "20251222T183000Z",
  "fetched_at": "2025-12-23T00:22:44.609575+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "United States",
  "raw_data": {
    "url": "https://www.cancertherapyadvisor.com/news/komzifti-approved-for-adults-with-r-r-npm1-mutated-aml/",
    "url_mobile": "",
    "title": "Komzifti Approved for Adults With R / R NPM1 - Mutated AML",
    "seendate": "20251222T183000Z",
    "socialimage": "https://www.cancertherapyadvisor.com/wp-content/uploads/sites/12/2025/12/Komzifti-Kura-Onc-Kyowa-Kirin.jpg",
    "domain": "cancertherapyadvisor.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}